Sanofi collaborates with MJFF on Parkinson’s disease treatment
Sanofi announced in late April that it has entered into a collaboration with the Michael J. Fox Foundation (MJFF) to conduct a clinical trial to assess the safety and tolerability of AVE 8112, a Sanofi phosphodiesterase type 4 (PDE4) inhibitor, in patients with Parkinson’s disease
To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.
Here are some related topics that may interest you:
Published In
Volume 8 - Issue 6 | June 2012
June 2012
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Rapid DNA-to-mRNA workflows help scientists keep pace with rapidly evolving cancer through personalized vaccines.
Understand how a human-relevant in vitro model can be used to improve next generation risk assessment (NGRA).
Explore the role of microphysiological systems in advancing human-relevant liver toxicity testing and mechanistic evaluation.
